Skip to: Content
Skip to: Site Navigation
Skip to: Search

WEDNESDAY, NOVEMBER 25, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter


0

FDA May Strengthen Chantix Label

Anti-smoking drug linked to more seizures, accidents

Share

(Newser) – The FDA may beef up its warning for the anti-smoking drug Chantix after an increase in the number of serious incidents linked to the drug, the Wall Street Journal reports. A drug-safety group tallied 1,001 reports of patients suffering seizures, blackouts, and loss of motor control—some while driving—in three months. The figure is more than the combined total of incidents linked to the top 10 prescription drugs.

Pfizer says it will “stand by the efficacy and safety” of Chantix. It claims the reports are “unverifiable and lack sufficient medical information to draw any conclusions," and that nicotine withdrawal could be the culprit instead. The FDA already is reviewing Chantix for links to depression and suicidal behavior. Once nearing $1 billion in annual sales, Chantix sales stopped short of $100 million last quarter.

Margaret Bastian says she had problems with the drug Chantix.
Margaret Bastian says she had problems with the drug Chantix.   (AP Photo/David Duprey)
Chantix promised a pleasure pathway for quitters, but has been linked to depression and serious injuries.
Chantix promised a pleasure pathway for quitters, but has been linked to depression and serious injuries.   (Flickr)
Pfizer dismisses the report and says it will
Pfizer dismisses the report and says it will "stand by the efficacy and safety profile of Chantix."   (AP Photo/Mary Altaffer)
« Prev« Prev | Next »Next » Slideshow
0 comments
VIEWING:
 
LEAVE A
COMMENT
Comment Policy
Facebook ConnectPost this comment to Facebook?

After connecting you will have the option to post your comment on your Facebook profile.